中国药科大学

刘李，男，中共党员，博士，副教授，博士研究生导师，现任中国药科大学药学院药代研究中心教师。

1、学习、工作经历

1999.9~2003.6中国药科大学药学专业（本科）
2004.9~2007.6中国药科大学药理学专业（硕士，导师：刘晓东教授）
2007.9~2010.6中国药科大学药剂学专业（博士，导师：刘晓东教授）
2010.7~2012.4中国药科大学讲师
2012.5~2013.5中国药科大学副教授
2013.6~至今中国药科大学副教授、硕士研究生导师

2015.6~至今中国药科大学副教授、博士研究生导师

2、科研与教学

主要研究方向为药物代谢动力学。科研上主持2011年国家自然科学基金青年项目1项（基于胰高血糖素样肽-1释放调控诠释人参二醇型皂苷抗糖尿病作用及其机制，81102503）、2014年国家自然科学基金面上项目1项（基于CYP3A等CYP450酶活性诱导诠释阿托伐他汀等他汀类药物诱发新生糖尿病和加重糖尿病症状的作用及机制，81473273）、2015年和2014年中国药科大学中央高校研究项目各1项；参与1项国家自然科学基金（81373482）和3项科技部“重大新药创制”（2011ZX09102-009、2011ZX091022-022、2009ZX09501-003）的研究；主持创新药物的临床前药代动力学研究共5项；协助指导已毕业博士研究生8人、硕士生15人，独立指导硕士研究生4人、本科实习生16人。

教学上主讲本科生《药物代谢动力学》和《临床药物代谢动力学》课程，担任药理学、药代动力学、临床药代动力学实验授课。指导的本科论文一篇获2013年校级本科优秀毕业论文，一篇获2011年江苏省普通高校本专科优秀毕业设计论文优秀指导教师三等奖（排名2）。主持2014年“中国药科大学实验教学改革研究重点课题”1项，主持“中国药科大学教学改革研究一般课题”2项。指导2014年度“国家级大学生创新创业训练计划项目”和2013年度“江苏省大学生创新创业训练计划项目”各1项。

3、近年来发表有代表性学术论文(*通讯作者)

1. Liu C, Hu M, Guo H, Zhang M, Zhang J, Li F, Zhong Z, Chen Y, Li Y, Xu P, Li J, Liu L*, Liu X*. Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats Following Oral Administration. Drug Metab Dispos. 2015; doi:10.1124/dmd.115.064881

2. Li F, Xu D, Shu N, Zhong Z, Zhang M, Liu C, Ling Z, Liu L*, Liu X*. Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution. Xenobiotica. 2015; 45(9): 794-802.

3. Jiang S, Zhao W, Chen Y, Zhong Z, Zhang M, Li F, Xu P, Zhao K, Li Y, Liu L*, Liu X*. Paroxetine decreased plasma exposure of glyburide partly via inhibiting intestinal absorption in rats. Drug Metab Pharmacokinet.  2015; 30(3): 240-6.

4. Li J, Guo HF, Liu C, Zhong Z, Liu L*, Liu XD*. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015; 54(2):179-93.

5. Liu L, Liu XD*. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014; 5: 273.

6. Zhang J, Zhang M, Sun B, Li Y, Xu P, Liu C, Liu L*, Liu X*. Hyperammonemia enhances the function and expression of P-glycoprotein and Mrp2 at the blood-brain barrier through NF-κB. J Neurochem. 2014 Dec; 131(6):791-802.

7. Xu D, Li F, Zhang M, Zhang J, Liu C, Hu MY, Zhong ZY, Jia LL, Wang DW, Wu J, Liu L*, Liu XD*. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2014; 35(9): 1215-25.

8. Liu C, Hu MY, Zhang M, Li F, Li J, Zhang J, Li Y, Guo HF, Xu P, Liu L*, Liu XD*. Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. Metabolism. 2014; 63(10): 1342-51.

9. Li F, Zhang M, Xu D, Liu C, Zhong ZY, Jia LL, Hu MY, Yang Y, Liu L*, Liu XD*. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin. 2014; 35(6): 792-805.

10. Li J, Wang X, Liu H, Guo H, Zhang M, Mei D, Liu C, He L, Liu L*, Liu X*. Impaired hepatic and intestinal ATP-binding cassette transporter G5/8 was associated with high exposure of β-sitosterol and the potential risks to blood-brain barrier integrity in diabetic rats. J Pharm Pharmacol. 2014; 66(3):428-36.

11. Hu N, Hu MY, Duan R, Liu C, Guo HF, Zhang M, Yu YL, Wang XT, Liu L*, Liu XD*. The increased levels of fatty acids contributed to induction of hepatic CYP3A4 activityinduced by diabetes. An in vitro evidence from HepG2 cell and Fa2N-4 cell lines. J Pharmacol Sci. 2014; 124(4): 433-44.

12. Jia LL, Zhong ZY, Li F, Ling ZL, Chen Y, Zhao WM, Li Y, Jiang SW, Xu P, Yang Y, Hu MY, Liu L*, Liu XD*. The aggravation of clozapine-induced hepatotoxicity by glycyrrhetinic Acid in rats. J Pharmacol Sci. 2014; 124(4): 468-79.

13. Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L*, Liu X*. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci. 2013; 102(8): 2819-36.

14. Liu C, Zhang M, Hu MY, Guo HF, Li J, Yu YL, Jin S, Wang XT, Liu L*, Liu XD*. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol. 2013; 217(2):185-96.

15. Yu Y, Wang X, Liu C, Yao D, Hu M, Li J, Hu N, Liu L*, Liu X*. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013; 266(3): 375-84.

16. Liu H, Liu L [Co-first author], Li J, Mei D, Duan R, Hu N, Guo H, Zhong Z, Liu X. Combined Contributions of Impaired Hepatic CYP2C11 and Intestinal Bcrp Activities and Expressions to Increased Exposure of Oral Glibenclamide in Streptozotocin-induced Diabetic Rats. Drug Metab Dispos. 2012; 40(6): 1104-12.

17. Duan R, Hu N, Liu HY, Li J, Guo HF, Liu C, Liu L*, Liu XD*. Biphasic regulation of P-glycoprotein function and expression by NO donors in Caco-2 cells. Acta Pharmacol Sin. 2012 Jun;33(6):767-74.

18. Yao D*, Liu L*, Jin S, Li J, Liu XD. Overexpression of multidrug resistance-associated protein 2 in the brain of pentylenetetrazole-kindled rats. Neuroscience. 2012; 227: 283-92.

19. Liu L, Yu YL, Liu C, Wang XT, Liu XD, Xie L. Insulin deficiency induces abnormal increase in intestinal disaccharidase activities and expression under diabetic states, evidences from in vivo and in vitro study. Biochem Pharmacol. 2011; 82(12): 1963-70. [IF: 4.576]

20. Liu L, Pan X, Liu HY, Liu XD, Yang HW, Xie L, Cheng JL, Fan HW, Xiao DW. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin. 2011; 32(10): 1285-93.

21. Liu L, Ju HL, Zhang J, Liang Y, Liu XD, Xie L, Wang GJ. Development and validation of an LC-MS/MS method for determination of vorinostat in beagle dog plasma and its application to a pharmacokinetic study. Asian J Pharmacodyn Pharmacokinet. 2010; 10(3): 209-219.

22. Liu L, Yu YL, Yang JS, Li Y, Liu YW, Liang Y, Liu XD, Xie L, Wang GJ.  Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381(4): 371-81.

23. Liu L, Deng YX, Liang Y, Pang XY, Liu XD, Liu YW, Yang JS, Xie L, Wang GJ. Increased oral AUC of baicalin in streptozotocin-induced diabetic rats due to the increased activity of intestinal β-glucuronidase. Planta Med. 2010; 76(1): 70-5.

4、联系方式

(1)电话：025-83271006

(2)手机：13914732571

(3)E-mail：liulee@yeah.net